Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Anixa Biosciences Inc's Business Segments
Anixa Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Cancer Vaccines
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Cancer Vaccines0%
- Cart Therapeutics0%
- Other0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Cancer Vaccines | - | - |
| Cart Therapeutics | - | - |
| Other | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Cancer Vaccines0%
- Cart Therapeutics0%
- Other0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Cancer Vaccines | - | - |
| Cart Therapeutics | - | - |
| Other | - | - |
Description of Anixa Biosciences Inc
Anixa Biosciences Inc is a publicly held biotechnology company that specializes in cancer treatment and detection technologies. Founded in 1982, the company is headquartered in San Jose, California and operates with key partnerships in academic research institutions and hospitals around the United States.
The mission of Anixa Biosciences Inc is to develop and market innovative cancer diagnostics and therapies that improve patient outcomes and reduce healthcare costs. The company's product focus is on developing diagnostic tests and immunotherapies for cancer detection and treatment.
One of Anixa's most promising products is its liquid biopsy technology, Cchek, which is a non-invasive blood test for early detection of cancer. Cchek utilizes artificial intelligence and machine learning algorithms to analyze circulating tumor cells (CTCs) and other biomarkers in a patient's blood sample to accurately identify early-stage cancer.
Anixa's additional cancer therapies in development include:
- CAR-T therapy for ovarian cancer
- vaccine for breast cancer
- prostate cancer drug
The company has obtained several patents for its cancer detection and therapy technologies and collaborations with leading academic institutions like Cleveland Clinic and The Moffitt Cancer Center.
Anixa is led by an experienced team of cancer researchers and executives that aim to bring their innovative cancer therapies and diagnostic tests to market. The company is publicly traded on the NASDAQ under the ticker symbol ANIX.
The mission of Anixa Biosciences Inc is to develop and market innovative cancer diagnostics and therapies that improve patient outcomes and reduce healthcare costs. The company's product focus is on developing diagnostic tests and immunotherapies for cancer detection and treatment.
One of Anixa's most promising products is its liquid biopsy technology, Cchek, which is a non-invasive blood test for early detection of cancer. Cchek utilizes artificial intelligence and machine learning algorithms to analyze circulating tumor cells (CTCs) and other biomarkers in a patient's blood sample to accurately identify early-stage cancer.
Anixa's additional cancer therapies in development include:
- CAR-T therapy for ovarian cancer
- vaccine for breast cancer
- prostate cancer drug
The company has obtained several patents for its cancer detection and therapy technologies and collaborations with leading academic institutions like Cleveland Clinic and The Moffitt Cancer Center.
Anixa is led by an experienced team of cancer researchers and executives that aim to bring their innovative cancer therapies and diagnostic tests to market. The company is publicly traded on the NASDAQ under the ticker symbol ANIX.
Anixa Biosciences Inc. operates in the dynamic field of biotechnology, focusing on innovative approaches to both cancer detection and treatment. The company is structured into two primary segments, each dedicated to distinct areas of investigation and product development within oncology.
Segments
1. Therapeutics Segment:
The Therapeutics segment is dedicated to the creation of groundbreaking oncology therapies aimed at treating various forms of cancer. Anixa is committed to leveraging cutting-edge technologies and research to develop therapies that can significantly improve patient outcomes.
2. Diagnostics Segment:
The Diagnostics segment specializes in the development of advanced diagnostic tests that allow for the early detection of cancer and other diseases. This segment is particularly focused on creating tools and methodologies to identify cancers at a stage when they are most treatable, thus enhancing the efficacy of subsequent therapeutic interventions.
Products
1. Cchek:
Cchek stands at the forefront of Anixas product offerings as their flagship cancer detection technology. Utilizing Artificial Intelligence (AI) and Machine Learning (ML) algorithms, Cchek analyzes a single blood sample to detect the presence of various cancers. The innovation lies in its ability to identify novel biomarkers associated with different cancers, enabling the early-stage detection of these diseases. This non-invasive approach not only enhances the earlier diagnosis of cancer but also has the potential to reduce the costs and burdens associated with advanced-stage treatments.
2. CAR-T Cell Therapies:
Anixa is also advancing the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, which represent a revolutionary approach to cancer immunotherapy. By engineering a patient’s own T cells to express specific receptors that target cancer cells, these therapies aim to harness the body’s immune response to effectively eliminate malignant cells. Currently in preclinical development, Anixa’s CAR-T therapies are designed to target various types of solid tumors and hematological cancers, expanding treatment options in the oncology field.
3. SiNPeX:
The SiNPeX technology is a nanoparticle-based gene delivery system developed by Anixa to enable efficient and targeted delivery of therapeutic genes to specific cells within the body. This innovative approach holds significant promise for the treatment of a wide array of conditions, ranging from genetic disorders and autoimmune diseases to various forms of cancer. SiNPeX aims to improve the precision and efficacy of gene therapies, potentially leading to more effective treatment modalities.
Services
1. Licensing:
Anixa offers robust licensing opportunities for its proprietary technology platforms, including Cchek. This allows other companies to integrate Anixas innovations into their own healthcare solutions, thereby expanding the reach and application of their technologies across the healthcare landscape.
2. Collaborations:
The company actively engages in multiple collaborative agreements with academic institutions and industry partners to accelerate the development of its technology platforms. These collaborations are instrumental in furthering research related to CAR-T cell therapies and nanoparticle-based gene delivery systems, promoting shared knowledge and resources for enhanced research outcomes.
3. Consulting:
Anixa provides consulting services to businesses interested in developing their own oncology-related technologies. With its deep expertise in cancer detection and treatment innovations, Anixa serves as a valuable partner, offering insights and guidance to organizations looking to enrich their development pipelines and bring novel cancer therapies to market.
Overall, Anixa Biosciences Inc. is positioned as a forward-thinking entity in biotechnology, uniquely combining diagnostic and therapeutic innovations aimed at combating cancer. Through its extensive product portfolio and service offerings, the company is poised to make significant contributions to the fields of oncology and diagnostics.
Segments
1. Therapeutics Segment:
The Therapeutics segment is dedicated to the creation of groundbreaking oncology therapies aimed at treating various forms of cancer. Anixa is committed to leveraging cutting-edge technologies and research to develop therapies that can significantly improve patient outcomes.
2. Diagnostics Segment:
The Diagnostics segment specializes in the development of advanced diagnostic tests that allow for the early detection of cancer and other diseases. This segment is particularly focused on creating tools and methodologies to identify cancers at a stage when they are most treatable, thus enhancing the efficacy of subsequent therapeutic interventions.
Products
1. Cchek:
Cchek stands at the forefront of Anixas product offerings as their flagship cancer detection technology. Utilizing Artificial Intelligence (AI) and Machine Learning (ML) algorithms, Cchek analyzes a single blood sample to detect the presence of various cancers. The innovation lies in its ability to identify novel biomarkers associated with different cancers, enabling the early-stage detection of these diseases. This non-invasive approach not only enhances the earlier diagnosis of cancer but also has the potential to reduce the costs and burdens associated with advanced-stage treatments.
2. CAR-T Cell Therapies:
Anixa is also advancing the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, which represent a revolutionary approach to cancer immunotherapy. By engineering a patient’s own T cells to express specific receptors that target cancer cells, these therapies aim to harness the body’s immune response to effectively eliminate malignant cells. Currently in preclinical development, Anixa’s CAR-T therapies are designed to target various types of solid tumors and hematological cancers, expanding treatment options in the oncology field.
3. SiNPeX:
The SiNPeX technology is a nanoparticle-based gene delivery system developed by Anixa to enable efficient and targeted delivery of therapeutic genes to specific cells within the body. This innovative approach holds significant promise for the treatment of a wide array of conditions, ranging from genetic disorders and autoimmune diseases to various forms of cancer. SiNPeX aims to improve the precision and efficacy of gene therapies, potentially leading to more effective treatment modalities.
Services
1. Licensing:
Anixa offers robust licensing opportunities for its proprietary technology platforms, including Cchek. This allows other companies to integrate Anixas innovations into their own healthcare solutions, thereby expanding the reach and application of their technologies across the healthcare landscape.
2. Collaborations:
The company actively engages in multiple collaborative agreements with academic institutions and industry partners to accelerate the development of its technology platforms. These collaborations are instrumental in furthering research related to CAR-T cell therapies and nanoparticle-based gene delivery systems, promoting shared knowledge and resources for enhanced research outcomes.
3. Consulting:
Anixa provides consulting services to businesses interested in developing their own oncology-related technologies. With its deep expertise in cancer detection and treatment innovations, Anixa serves as a valuable partner, offering insights and guidance to organizations looking to enrich their development pipelines and bring novel cancer therapies to market.
Overall, Anixa Biosciences Inc. is positioned as a forward-thinking entity in biotechnology, uniquely combining diagnostic and therapeutic innovations aimed at combating cancer. Through its extensive product portfolio and service offerings, the company is poised to make significant contributions to the fields of oncology and diagnostics.